Molecular Subtype
Triple-Negative Breast Carcinoma
CI-CAN-00008567TNBCExplore in graph →
417 active trials3 approved drugs8 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00008567TNBCExplore in graph →
Clinical trials
950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02954874 | Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | active not recruiting | Phase 3 | 1,195 | National Cancer Institute (NCI)NIH | 3 | Aug 31, 2026 | clinicaltrials |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | active not recruiting | Phase 3 | 392 | Biotheus Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT06382142 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) | active not recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer(ISIdE) | active not recruiting | Phase 3 | 96 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05347134 | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 254 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT02488967 | Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | active not recruiting | Phase 3 | 782 | NRG OncologyOTHER | 2 | May 6, 2026 | clinicaltrials |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer(SASCIA) | active not recruiting | Phase 3 | 1,332 | GBG Forschungs GmbHOTHER | 7 | Apr 22, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT06519370 | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | active not recruiting | Phase 3 | 350 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT05382286 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-04) | active not recruiting | Phase 3 | 443 | Gilead SciencesINDUSTRY | 28 | Sep 18, 2025 | clinicaltrials |
| NCT04335669 | NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | active not recruiting | Phase 3 | 325 | Lund University HospitalOTHER | 2 | Sep 12, 2025 | clinicaltrials |
| NCT03562637 | Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | active not recruiting | Phase 3 | 575 | OBI Pharma, IncINDUSTRY | 13 | May 9, 2025 | clinicaltrials |
| NCT03168880 | A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer(TNBC) | active not recruiting | Phase 3 | 720 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04296175 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)(CITRINE) | active not recruiting | Phase 3 | 808 | Fudan UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2026source: clinicaltrials